Cardiovascular symposium 2026: advancing knowledge in atrial fibrillation, ischaemic heart disease and heart failure

Nik Mustaffa Shapri, Nik Aisyah Najwa and Taridi, Nur Syazwani and Abd Wahab, Mohd Shahezwan and Ismail, Farhana Fakhira and Zulkifly, Hanis Hanum (2026) Cardiovascular symposium 2026: advancing knowledge in atrial fibrillation, ischaemic heart disease and heart failure. Prescription, 5 (6): 11. pp. 1-2.

Official URL: https://pharmacy.uitm.edu.my/

Abstract

This academic report documents and analyzes the clinical paradigms, evidence-based pharmacology, and therapeutic milestones established at the "Cardiovascular Symposium 2026: Advancing Knowledge in Atrial Fibrillation, Ischaemic Heart Disease, and Heart Failure." Cardiovascular diseases (CVDs) remain the leading driver of global mortality, necessitating continuous medical education to bridge the gap between breakthrough clinical trials and bedside patient management. To synthesize the multi-faceted clinical insights presented during this symposium, this report evaluates the proceedings across three primary pathological axes: (1) Atrial Fibrillation (AF) and Electrophysiological Innovations, focusing on the paradigm shift toward early rhythm control, the application of pulsed field ablation (PFA) to mitigate pulmonary vein complications, and updated direct oral anticoagulant (DOAC) dosing algorithms for stroke prevention; (2) Ischaemic Heart Disease (IHD) and Revascularization Dynamics, analyzing long-term outcomes of dual antiplatelet therapy (DAPT) configurations, advanced intravascular imaging (IVUS/OCT) during complex percutaneous coronary interventions, and myocardial preservation protocols; and (3) Heart Failure (HF) Therapeutics and Neurohormonal Modulation, evaluating the clinical optimization of the "four pillars" of medical therapy—including SGLT2 inhibitors and ARNIs—across both reduced and preserved ejection fraction (HFrEF/HFpEF) phenotypes. The symposium proceedings emphasize that integrating multidisciplinary care teams and utilizing real-time remote biometric monitoring significantly improves patient-reported health-related quality of life (HRQoL) and lowers 30-day readmission indices. Ultimately, this document provides an applied clinical framework and administrative reference guide for cardiologists, clinical pharmacists, and healthcare administrators looking to embed cutting-edge cardiovascular guidance into modern institutional practice.

Metadata

Item Type: Article
Creators:
Creators
Email / ID Num.
Nik Mustaffa Shapri, Nik Aisyah Najwa
aisyahnajwa@uitm.edu.my
Taridi, Nur Syazwani
nursyazwani91@uitm.edu.my
Abd Wahab, Mohd Shahezwan
mohdsh2790@uitm.edu.my
Ismail, Farhana Fakhira
farhanafakhira@uitm.edu.my
Zulkifly, Hanis Hanum
hanish2984@uitm.edu.my
Subjects: R Medicine > R Medicine (General) > Medical technology
R Medicine > RD Surgery > Surgery by region, system, or organ > Cardiovascular system
Divisions: Universiti Teknologi MARA, Selangor > Puncak Alam Campus > Faculty of Pharmacy
Journal or Publication Title: Prescription
Volume: 5
Number: 6
Page Range: pp. 1-2
Keywords: Cardiovascular symposium 2026, Atrial fibrillation, Ischaemic heart disease, Heart failure, Pulsed field ablation, Neurohormonal modulation, Clinical trial translation, Evidence-based cardiology
Date: June 2026
URI: https://ir.uitm.edu.my/id/eprint/141918
Edit Item
Edit Item

Download

[thumbnail of 141918.pdf] Text
141918.pdf

Download (2MB)

ID Number

141918

Indexing

Statistic

Statistic details